Abiomed gets US boost for two major cardiac devices
This article was originally published in Clinica
In what represents two key developments for the company, Abiomed has gained US market approval for a major new addition to its commercial product portfolio and has received a favourable decision from the FDA regarding its replacement heart, Abiocor.
You may also be interested in...
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.